vaccin
repres
costeffect
sometim
costsav
safe
intervent
provid
substanti
health
econom
benefit
individu
american
popul
signific
financi
support
deriv
american
send
dime
presid
franklin
roosevelt
nation
foundat
infantil
paralysi
march
dime
led
commerci
polio
vaccin
yield
substanti
us
health
financi
benefit
mani
decad
polio
vaccin
introduct
across
us
also
help
establish
nation
enthusiasm
vaccin
earli
develop
current
us
vaccin
enterpris
one
studi
estim
us
govern
financi
invest
contribut
substanti
develop
first
approv
twothird
new
vaccin
approv
us
notabl
earli
american
experi
polio
vaccin
introduct
also
help
establish
foundat
regulatori
element
us
vaccin
enterpris
set
legal
preced
compens
vaccineassoci
injuri
success
lawsuit
built
legal
preced
pursu
claim
pertussi
vaccin
manufactur
led
signific
drop
number
pertussi
vaccin
manufactur
result
consolid
market
increas
liabil
led
nearli
increas
price
pertussi
vaccin
one
remain
manufactur
pass
cost
liabil
insur
purchas
situat
rais
concern
vaccin
purchas
vaccin
manufactur
exit
market
complet
stabil
vaccin
enterpris
overal
us
govern
respond
liabil
issu
establish
us
vaccin
injuri
compens
program
vicp
us
vaccin
enterpris
support
aspect
immun
continu
encourag
innov
invest
develop
new
vaccin
demand
american
howev
despit
limit
histor
recommend
creat
fund
support
invest
vaccin
safeti
recent
legisl
support
innov
new
vaccin
st
centuri
cure
act
public
law
date
us
lack
financi
incent
fund
innov
vaccin
deliveri
technolog
increment
improv
exist
vaccin
recent
review
vaccin
patch
identifi
suffici
matur
technolog
consid
vaccin
patch
platform
highlight
lack
financi
incent
barrier
commerci
licens
vaccin
patch
new
product
briefli
vaccin
manufactur
would
need
make
substanti
invest
conduct
largescal
clinic
trial
ii
adopt
scale
new
manufactur
capac
make
patch
good
manufactur
practic
iii
manag
complic
regulatori
submiss
requir
new
platform
new
vaccin
product
separ
recent
review
experi
us
vicp
show
rel
low
rate
vaccineassoci
injuri
claim
overal
report
strong
financi
perform
vicp
trust
fund
review
also
identifi
shoulder
injuri
relat
vaccin
administr
sirva
claim
relat
inject
vaccin
signal
import
safeti
categori
relat
vaccin
deliveri
emphas
import
vicp
protect
manufactur
liabil
vaccineassoci
injuri
includ
sirva
perspect
suggest
opportun
creat
new
us
fund
mechan
target
provid
financi
incent
vaccin
manufactur
invest
commerci
innov
vaccin
deliveri
technolog
reduc
elimin
sirva
specif
suggest
alloc
fraction
exist
vicp
trust
fund
andor
futur
divers
fraction
expect
incom
vaccin
excis
tax
creat
new
incent
fund
support
translat
research
develop
vaccin
deliveri
technolog
show
promis
reduc
elimin
futur
vicp
claim
suggest
use
sirva
test
case
explor
use
fraction
vicp
trust
fund
support
activ
reduc
futur
vicp
claim
perspect
assum
reader
appreci
complex
us
vaccin
enterpris
challeng
vaccin
financ
briefli
us
market
divid
vaccin
financ
privat
sector
privat
insur
public
sector
public
sector
vaccin
children
vfc
program
guarante
financi
support
elig
children
receiv
vaccin
recommend
us
advisori
committe
immun
practic
acip
vfc
support
public
purchas
nearli
half
pediatr
vaccin
public
ie
us
govern
purchas
public
purchas
vaccin
ensur
exist
larg
market
vaccin
recommend
routin
use
act
creat
vfc
stipul
public
price
vaccin
applic
excis
tax
increas
public
price
vaccin
may
adjust
inflat
use
consum
price
index
requir
maintain
constant
real
preexcis
tax
public
price
vaccin
avail
may
constant
nomin
excis
tax
per
vaccin
antigen
vicp
trust
fund
ad
per
dose
lack
chang
inflat
excis
tax
impli
slight
declin
real
total
public
price
time
vaccin
exist
contrast
us
privat
market
preexcis
vaccin
price
similarli
constrain
although
nomin
per
vaccin
excis
tax
appli
thu
manufactur
potenti
recov
cost
associ
improv
andor
postmarket
activ
exist
vaccin
us
privat
sector
repres
import
opportun
vaccin
manufactur
cover
cost
postmarket
research
margin
improv
product
process
andor
productrel
commun
activ
includ
invest
made
counter
claim
harm
associ
vaccin
eg
defend
product
fals
claim
us
vaccin
market
includ
substanti
barrier
entri
eg
high
prelicens
invest
recover
commerci
success
market
high
regulatori
cost
ie
licens
complianc
liabil
demand
high
volum
low
price
largest
buyer
ie
us
govern
vfc
imperfect
market
condit
favor
economi
scale
come
one
vaccin
produc
monopoli
oligopoli
serv
entir
market
mani
vaccin
lack
competit
reduc
incent
vaccin
manufactur
invest
innov
increment
chang
affect
market
share
thu
although
technolog
innov
eg
adjuv
enhanc
potenc
vaccin
vial
monitor
new
vaccin
deliveri
technolog
could
potenti
make
exist
vaccin
effect
cheaper
produc
less
like
wast
andor
easier
administ
limit
recognit
potenti
benefit
improv
product
combin
cost
time
develop
licensur
serv
barrier
invest
us
market
howev
market
size
potenti
return
appear
justifi
manufactur
lead
notabl
except
like
develop
gsk
invest
develop
twodos
adjuv
despit
exist
licensur
use
onedos
led
substanti
effect
vaccin
offer
longerlast
protect
becam
prefer
vaccin
drove
market
similarli
dynavax
technolog
corpor
felt
encourag
develop
hepat
b
vaccin
hepbcpg
heplisav
requir
dose
primari
seri
compet
prevail
hepat
b
vaccin
requir
dose
acip
give
preferenti
recommend
hepbcpg
recommend
made
new
vaccin
equal
altern
vaccin
part
success
us
vaccin
enterpris
come
abil
vaccin
manufactur
financi
recov
invest
resourc
develop
new
vaccin
cost
develop
new
vaccin
typic
exceed
billion
current
us
dollar
spent
approxim
year
time
research
regulatori
test
complianc
develop
mass
product
capac
bring
new
licens
vaccin
product
market
complex
scienc
high
cost
uncertainti
overcom
multipl
challeng
cross
translat
valley
death
ie
larg
gap
basic
scientif
research
widespread
use
novel
therapeut
limit
interest
invest
vaccin
innov
degre
specif
manufactur
must
overcom
multipl
challeng
includ
need
determin
protect
immun
respons
demonstr
abil
vaccin
product
induc
typic
initi
involv
anim
studi
conduct
progress
larger
timeconsum
costli
often
unsuccess
human
clinic
studi
demonstr
safeti
efficaci
importantli
timeconsum
expens
step
must
repeat
substanti
modif
exist
vaccin
modifi
product
requir
minim
show
noninferior
safeti
andor
effect
compar
exist
product
demonstr
measur
benefit
order
receiv
preferenti
recommend
acip
reduc
enthusiasm
increment
improv
addit
spite
vicp
us
vaccin
manufactur
continu
face
assert
danger
vaccin
mani
case
made
individu
organ
seek
benefit
financi
lead
vaccin
manufactur
invest
resourc
might
otherwis
spend
innov
defend
safeti
exist
product
instead
addit
possibl
open
new
line
attack
modifi
vaccin
also
decreas
incent
innov
exist
product
particularli
given
high
cost
make
chang
associ
regulatori
activ
unless
innov
result
new
vaccin
establish
new
public
price
ie
anchor
may
price
sinc
vaccin
exist
opportun
set
new
higher
price
incentiv
innov
enabl
combin
vaccin
increas
overal
nation
spend
vaccin
need
overcom
intellectu
properti
right
issu
around
develop
combin
vaccin
use
compon
differ
manufactur
streamlin
regulatori
issu
around
combin
vaccin
repres
barrier
increas
develop
combin
vaccin
histor
face
uncertain
nonexist
market
regular
demand
vaccin
us
govern
success
creat
publicpriv
partnership
exampl
publicpriv
partnership
support
purchas
smallpox
anthrax
vaccin
address
bioterror
concern
spearhead
biomed
advanc
research
develop
author
barda
part
hh
offic
assist
secretari
prepared
respons
us
govern
also
devot
signific
resourc
support
research
develop
vaccin
emerg
infecti
diseas
face
wih
threat
eg
hiv
start
us
spend
billion
licens
vaccin
date
despit
invest
pandem
influenza
recent
ebola
zika
coronaviru
public
law
coronaviru
prepared
respons
supplement
appropri
act
enact
march
us
also
make
substanti
invest
select
product
annual
influenza
vaccin
invest
still
may
support
type
innov
requir
obtain
optim
significantli
improv
vaccin
addit
address
lack
incent
develop
vaccin
highli
uncertain
potenti
small
expect
market
emerg
infecti
diseas
may
lack
promis
commerci
profit
coalit
epidem
prepared
innov
cepi
launch
use
new
intern
fund
model
includ
support
usbas
bill
melinda
gate
foundat
explor
option
human
vaccin
administr
includ
consider
possibl
rout
entri
bodi
wide
rang
strategi
current
use
syring
needl
inject
vaccin
skin
barrier
repres
domin
vaccin
deliveri
technolog
although
us
market
includ
limit
number
licens
oral
eg
oral
rotaviru
vaccin
intranas
eg
vaccin
vaccin
repres
candid
oral
intranas
administr
howev
us
vaccin
take
advantag
rout
transmiss
use
live
attenu
virus
bacteria
develop
uslicens
follow
mani
year
us
govern
invest
research
develop
coldadapt
live
attenu
influenza
vaccin
deliv
influenza
vaccin
use
devic
aerosol
vaccin
nasal
passag
thu
elimin
needlerel
risk
includ
dispos
sharp
approv
us
offer
easi
deliveri
captur
increas
market
share
howev
subsequ
face
challeng
unrel
rout
administr
respect
flu
strain
match
led
rel
lower
efficaci
compar
avail
inject
flu
vaccin
lower
efficaci
affect
inclus
list
vaccin
recommend
acip
cover
vfc
fund
public
purchas
strain
flu
season
albeit
chang
vaccin
led
full
recommend
use
later
season
experi
serv
cautionari
exampl
novel
deliveri
technolog
eg
vaccin
patch
could
similarli
face
efficaci
challeng
market
share
impact
may
relat
differ
strain
vaccin
circul
strain
adjuv
excipi
choic
deliveri
mechan
past
experi
fail
attempt
develop
vaccin
product
use
altern
deliveri
technolog
also
influenc
vaccin
manufactur
decis
type
innov
eg
aerosol
transcutan
measl
vaccin
deliveri
technolog
pass
trial
criterion
noninferior
clinic
trial
swiss
experi
increas
incid
bell
palsi
associ
intranas
inactiv
influenza
vaccin
influenza
season
contain
escherichia
coli
heatlabil
toxin
mucos
adjuv
histor
approach
develop
needlefre
deliveri
technolog
otherwis
inject
vaccin
led
numer
design
multius
nozzl
jet
injector
found
widespread
use
mass
campaign
howev
us
discontinu
use
multius
nozzl
jet
injector
due
potenti
bloodborn
pathogen
transmiss
risk
insuffici
clean
multipl
use
subsequ
develop
disposablesyring
jet
injector
led
function
altern
us
use
occur
vaccin
vaccin
label
explicitli
allow
use
specif
devic
use
disposablesyring
jet
injector
thu
increas
cost
deliveri
get
indic
includ
label
eg
afluria
season
influenza
vaccin
pay
increment
cost
devic
dispos
compon
compar
syring
needl
date
devic
see
widespread
use
us
howev
follow
us
food
drug
administr
approv
seqiru
vaccin
administr
pharmajet
devic
adult
use
needlefre
vaccin
deliveri
devic
increas
new
biomateri
technolog
also
suggest
signific
promis
vaccin
deliveri
use
vaccin
patch
despit
long
path
notabl
failur
deliv
vaccin
skin
use
array
submicron
project
although
licens
vaccin
patch
exist
date
us
case
us
vaccin
manufactur
add
featur
vaccin
product
requir
use
addit
resourc
exclus
benefit
downstream
user
eg
eas
deliveri
less
wast
expect
recov
cost
featur
vaccin
price
thu
inject
vaccin
vaccin
manufactur
would
need
see
signific
signal
market
indic
substanti
demand
invest
altern
deliveri
technolog
exist
vaccin
product
context
current
us
market
clear
incent
exist
current
vaccin
manufactur
invest
innov
increas
cost
may
save
cost
part
health
system
mani
opportun
compet
scarc
resourc
innov
one
opportun
explor
prioriti
innov
come
review
vicp
claim
eye
toward
invest
strategi
offer
potenti
reduc
futur
vicp
claim
specif
extent
innov
improv
exist
vaccin
andor
vaccin
deliveri
technolog
address
identifi
vaccin
safeti
issu
innov
offer
potenti
reduc
futur
vicp
claim
prior
review
vicp
claim
identifi
sirva
increasingli
import
injuri
categori
one
relat
directli
deliveri
inject
vaccin
notabl
consist
highest
number
vaccin
dose
annual
given
influenza
ie
million
dose
report
highest
number
vicp
claim
influenza
vaccin
expand
find
tabl
tabl
also
report
sirvaassoci
claim
pend
march
get
dismiss
adjud
pend
claim
relat
administr
influenza
vaccin
vicp
sirva
claim
continu
lead
compens
order
around
million
per
year
anticip
cumul
us
spend
million
vicp
sirva
claim
tabl
also
show
sirva
claim
involv
influenza
vaccin
deliv
adult
suggest
signific
opportun
avoid
vicp
claim
payout
associ
elimin
influenzarel
inject
injuri
recogn
mount
cost
injuri
vaccin
manufactur
current
lack
adequ
incent
fulli
invest
research
develop
need
promis
increment
improv
exist
vaccin
vaccin
deliveri
method
consid
creation
new
incent
fund
reduc
futur
sirva
claim
note
reduc
inject
also
provid
multipl
addit
benefit
fall
outsid
vicp
eg
elimin
occup
needlestick
injuri
reduc
sharp
dispos
requir
affect
health
system
enabl
vaccin
deliveri
personnel
need
train
deliv
inject
includ
selfadministr
ignor
like
extern
benefit
review
vicp
show
current
level
vaccin
injuri
compens
trust
fund
victf
continu
grow
rate
inflow
excis
tax
interest
incom
receiv
invest
fund
depart
treasuri
margin
exceed
expenditur
includ
payment
made
injuri
legal
represent
expens
associ
administr
program
propos
base
past
experi
amount
victf
set
asid
ensur
provis
payment
individu
entitl
compens
vaccinerel
advers
event
could
level
somewher
rang
billion
ie
nearli
billion
held
exist
claim
system
given
year
delay
process
claim
billion
reserv
fund
reach
nearli
billion
suggest
amount
necessari
level
could
go
fund
would
avail
support
costli
translat
studi
ie
phase
clinic
trial
postmarket
surveil
need
support
commerci
vaccin
product
design
prevent
potenti
futur
vaccin
injuri
could
oper
occur
divert
fraction
inflow
new
excis
tax
newli
creat
research
develop
fund
would
support
innov
vaccin
excis
tax
exist
ie
would
preclud
use
fund
new
vaccin
divert
fraction
maintain
victf
necessari
level
ie
account
interest
revenu
fund
well
depart
treasuri
would
continu
invest
anticip
level
amount
exist
victf
interest
incom
would
continu
accru
depart
treasuri
could
similarli
invest
fund
held
newli
creat
innov
fund
remain
unalloc
design
fund
specif
address
barrier
current
exist
perform
research
develop
need
prevent
futur
vicp
claim
appear
consist
origin
intent
vicp
propos
chang
would
use
fund
provid
manufactur
incent
improv
exist
vaccin
deliveri
technolog
process
would
need
put
place
evalu
alloc
research
develop
fund
would
suggest
process
involv
health
resourc
servic
administr
hrsa
divis
injuri
compens
program
dicp
administ
vicp
ensur
propos
research
develop
invest
hold
reason
promis
address
real
improv
vaccin
safeti
reduc
futur
vicp
claim
potenti
riskrisk
tradeoff
also
consid
eg
evalu
whether
propos
chang
aim
reduc
elimin
one
type
injuri
risk
may
increas
anoth
type
injuri
risk
propos
concept
offer
opportun
reward
exist
manufactur
suppli
vaccin
us
market
make
invest
make
exist
vaccin
deliveri
safer
american
prevent
futur
vicp
claim
process
alloc
monitor
fund
could
involv
establish
review
process
nation
institut
health
nation
vaccin
program
offic
perhap
concurr
follow
review
hrsa
dicp
propos
research
includ
potenti
reduc
compens
vaccin
injuri
chang
propos
incent
real
incent
requir
new
legisl
recogn
open
legisl
come
promis
improv
peril
divers
given
natur
us
democrat
system
creat
propos
incent
repres
rel
simpl
concept
could
occur
small
chang
recogn
chang
would
requir
suffici
consensu
legisl
pass
addit
chang
disrupt
primari
function
vicp
provid
payment
individu
entitl
compens
vaccinerel
advers
event
suggest
incent
could
lead
innov
reduc
vaccineassoci
injuri
improv
safeti
vaccin
deliveri
american
without
net
increas
tax
also
suggest
mechan
could
support
costli
clinic
trial
studi
current
serv
barrier
advanc
vaccin
deliveri
technolog
like
vaccin
patch
platform
addit
creat
incent
develop
vaccin
deliveri
technolog
like
vaccin
patch
suggest
mechan
use
sustain
fraction
vicp
trust
fund
creat
financi
incent
reduc
futur
sirva
claim
could
involv
studi
identifi
effect
intervent
train
healthcar
worker
pharmacist
deliv
vaccin
inject
avoid
shoulder
injuri
propos
mechan
could
also
potenti
use
support
studi
would
reduc
type
vaccineassoci
injuri
although
propos
suggest
modest
test
concept
overal
hope
greater
awar
sirva
improv
train
health
personnel
deliv
inject
vaccin
recogn
sirva
repres
vaccineassoci
injuri
cover
vicp
also
recogn
potenti
role
type
incent
motiv
develop
altern
vaccin
deliveri
technolog
includ
vaccin
patch
exampl
pull
mechan
prioriti
review
voucher
guarante
purchas
commit
andor
preferenti
acip
recommend
possibl
could
also
help
publicpriv
partnership
could
help
share
cost
risk
although
focus
us
market
recogn
global
market
vaccin
countri
benefit
us
invest
vaccin
innov
american
benefit
vaccin
develop
research
support
countri
focus
us
interest
perspect
sever
reason
first
recogn
import
us
invest
vaccin
promot
global
secur
believ
incent
innov
need
benefit
us
market
addit
familiar
us
vaccin
enterpris
encourag
colleagu
countri
consid
opportun
nation
govern
may
offer
incentiv
similar
invest
gavi
vaccin
allianc
strive
promot
faster
adopt
vaccin
andor
greater
vaccin
use
lowerincom
countri
repres
outflow
us
resourc
addit
although
increas
demand
product
lead
lower
price
normal
market
ie
increas
demand
allow
exist
buyer
share
benefit
lower
price
occur
economi
scale
gener
occur
global
vaccin
market
notabl
global
vaccin
market
includ
tier
price
enabl
earlier
adopt
greater
global
use
vaccin
creat
licens
develop
countri
lowerincom
countri
allow
lowerincom
countri
purchas
vaccin
lower
price
paid
industri
countri
tier
price
accomplish
use
exist
product
capac
alreadydevelop
product
sell
vaccin
price
reflect
margin
cost
product
make
afford
develop
countri
purchas
lower
price
facilit
technolog
transfer
manufactur
rel
higherincom
countri
manufactur
lowerincom
countri
produc
vaccin
significantli
lower
product
cost
howev
sinc
maintain
high
price
vaccin
pharmaceut
product
serv
mean
manufactur
recov
cost
research
develop
us
market
valu
innov
tier
price
mean
buyer
market
support
innov
realiz
benefit
share
cost
buyer
market
third
despit
potenti
us
invest
vaccin
innov
drive
global
vaccin
market
usbas
vaccin
manufactur
play
rel
small
role
global
market
vaccin
larg
due
domest
concern
price
global
tier
price
us
continu
pay
higher
health
care
cost
per
capita
rel
highincom
often
better
perform
health
system
public
concern
health
care
cost
drive
polici
congression
hear
earli
notabl
contribut
usbas
vaccin
manufactur
decis
particip
global
market
demand
tier
price
thu
instead
see
larg
number
vaccin
manufactur
compet
suppli
product
tier
price
differ
market
vaccin
market
highli
segment
character
monopolist
oligopolist
supplier
gener
sell
rel
ie
oligopsonist
larg
buyer
like
vfc
program
us
pan
american
health
organ
revolv
fund
countri
america
unicef
develop
countri
thu
vaccin
market
includ
rel
highpric
vaccin
target
rel
highincom
market
eg
singl
dose
combin
vaccin
lowerpr
multidos
vaccin
rel
lowerincom
countri
often
singl
manufactur
decreasingli
small
number
manufactur
serv
specif
market
overal
tier
price
offer
benefit
allow
lowerincom
countri
purchas
vaccin
price
afford
financ
innov
fall
countri
choos
afford
despit
challeng
hope
propos
lead
discuss
broad
rang
stakehold
potenti
creat
incent
help
improv
safeti
vaccin
deliveri
prevent
compens
vaccin
injuri
also
hope
greater
awar
sirva
improv
train
health
personnel
deliv
inject
vaccin
discuss
reaffirm
import
vicp
respect
provid
compens
sirva
protect
vaccin
manufactur
sirva
liabil
